Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
← catalyst calendarNCT06960577 · readout in 804 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
59
Countries
Australia, Brazil, Canada +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-15 | actual | When the study began enrolling |
| Primary completion | 2028-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Urinary Bladder Neoplasms
- Immune Checkpoint Inhibitors
- Methotrexate
- Vinblastine
- Doxorubicin
- Cisplatin
- Gemcitabine
Interventions
- Drug: Durvalumab
- Drug: Methotrexate
- Drug: Vinblastine
- Drug: Doxorubicin
- Drug: Cisplatin
- Drug: Durvalumab
- Drug: Gemcitabine
- Drug: Cisplatin
Primary outcome
what the primary-completion date above is the date OFThe safety of neoadjuvant durvalumab combined with ddMVAC or gem/cis prior to radical cystectomy (RC).
measured Up to 6 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed